Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?

Key Takeaways Cencora's U.S. Healthcare Solutions segment continues to drive growth, led by strong specialty demand.GLP-1 revenue rose 36% year over year but dipped 10% sequentially due to seasonal trends.International segment lags, with lowered outlook tied to weak clinical logistics and consulting demand.Cencora (COR) is slated to report third-quarter fiscal 2025 results on Aug. 6, before market open.In the last reported quarter, the company delivered an earnings surprise of 8.33%. COR’s earnings beat est ...